Side effects What are the most common side effects of Wegovy? Applies to Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition
“The most common adverse reactions for Wegovy® (incidence ≥5%) are nausea, diarrhea, vomiting, constipation, abdominal pain, dysesthesia, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and hair loss.1 ” (opens the source at this quote in a new tab) Copy Flag
“Table 3 shows adverse reactions reported in greater than or equal
to 2% of WEGOVY® 2.4 mg injection-treated adult patients and
more frequently than in the placebo group from these trials.
Table 3. Adverse Reactions (≥2% and Greater Than
Placebo) in WEGOVY® 2.4 mg Injection-
treated Adults with Obesity or Overweight for
Weight Reduction
Placebo
N=1,261
%
WEGOVY®
Injection (2.4 mg
Once Weekly)
N=2,116
%
Nausea
16
44
Diarrhea
16
30
Vomiting
6
24
Constipation
11
24
Abdominal Paina
10
20
Headache
10
14
Fatigueb
5
11
Dyspepsia
3
9
Dizziness
4
8
Abdominal Distension
5
7
Eructation
<1
7
Hypoglycemia in T2DMc
2
6
Flatulence
4
6
Gastroenteritis
4
6
Gastroesophageal Reflux
Disease
3
5
Gastritisd
1
4
Gastroenteritis Viral
3
4
Hair Loss
1
3
Dysesthesiae
1
2
a Includes abdominal pain, abdominal pain upper, abdominal pain lower,
gastrointestinal pain, abdominal tenderness, abdominal discomfort and
epigastric discomfort.
b Includes fatigue and asthenia.
c Defined as blood glucose <54 mg/dL with or without symptoms of
hypoglycemia or severe hypoglycemia (requiring the assistance of another
person) in patients with type 2 diabetes not on concomitant insulin (Study 3,
WEGOVY® N=403, Placebo N=402). See text below for further information
regarding hypoglycemia in patients with and without type 2 diabetes. T2DM =
type 2 diabetes mellitus.
d Includes chronic gastritis, gastritis, gastritis erosive, and reflux gastritis.
e Includes paresthesia, hyperesthesia, burning sensation, allodynia,
dysesthesia, skin burning sensation, pain of skin, and sensitive skin.” (opens the source at this quote in a new tab) Copy Flag
Note: Table 3 columns are placebo (N=1,261) then WEGOVY 2.4 mg injection (N=2,116), in % of patients, pooled from 3 placebo-controlled weight-reduction trials in adults.
How do Wegovy HD 7.2 mg side effects compare with 2.4 mg? Applies to Weight reduction in adults with obesity with the 7.2 mg once-weekly dose (Wegovy HD)
“The safety of WEGOVY® 7.2 mg injection was evaluated in two
72-week double-blinded randomized placebo-controlled 3-armed
trials (Study 8 and Study 9), including 1,311 patients with obesity
(BMI ≥30 kg/m2 ) exposed in the treatment arm with WEGOVY®
7.2 mg injection, 304 patients exposed in the treatment arm with
WEGOVY® 2.4 mg injection, and 303 patients exposed to placebo
[see Clinical Studies (14.2)]. After dosage escalation, 1,149 patients
received at least one dose of WEGOVY® 7.2 mg injection, and 578
patients received 7.2 mg for at least 1 year. Baseline characteristics
in the WEGOVY® 7.2 mg injection arm included a mean age of 49
years, 70% female, 85% White, 5% Asian, 8% Black or African
American, and 2% reported as other or unknown; and 5% were
Hispanic or Latino ethnicity. At baseline, mean BMI was 39.5 kg/
m2 , 52% with hypertension, 38% with dyslipidemia, 40% with a
BMI greater than 40 kg/m2 , and 14% with CV disease.
In these clinical trials, 5% of patients treated with 7.2 mg WEGOVY®
injection, 5% of patients treated with 2.4 mg of WEGOVY® injection
and 2% of patients treated with placebo permanently discontinued
treatment as a result of adverse reactions. The most common
adverse reactions leading to discontinuation were gastrointestinal
disorders: 3%, 3%, and 0.3%, for WEGOVY® 7.2 mg injection,
WEGOVY® 2.4 mg injection, and placebo, respectively.
Table 4 shows adverse reactions reported in greater than or equal
to 2% of WEGOVY® 7.2 mg injection and more frequently than
2.4 mg injection-treated and placebo-treated patients from these
studies.
Table 4. Adverse Reactions (2% and Greater Than
WEGOVY® 2.4 mg and Placebo) in WEGOVY®
7.2 mg Injection-treated Adults with Obesity
for Weight Reduction
Placebo
N=303
%
WEGOVY®
Injection
(2.4 mg Once
Weekly)
N=304
%
WEGOVY®
Injection
(7.2 mg Once
Weekly)
N=1,311
%
Nausea
13
35
39
Vomiting
6
16
22
Dysesthesiaa
0
6
22
Constipation
8
19
20
Abdominal painb
7
9
12
Fatiguec
5
9
11
Headache
7
8
9
Dizzinessd
1
5
6
Hair loss
1
3
6
Flatulence
2
2
4
a Includes allodynia, burning sensation, dysesthesia, hyperesthesia,
hyperpathia, pain of skin, paresthesia, sensitive skin, skin burning sensation,
skin discomfort, and skin sensitization.
b Includes abdominal pain, abdominal pain upper, abdominal pain lower,
gastrointestinal pain, abdominal tenderness, abdominal discomfort and
epigastric discomfort.
c Includes fatigue and asthenia.
d Includes dizziness and dizziness postural.” (opens the source at this quote in a new tab) Copy Flag
Note: Table 4 columns are placebo (N=303), WEGOVY 2.4 mg (N=304), and WEGOVY 7.2 mg (N=1,311), in % of patients. The Clinical Product Review describes the same pool as the STEP UP and STEP UP T2D trials.
What are the side effects of the Wegovy pill? Applies to Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition, with Wegovy tablets (pill)
How long do Wegovy pill side effects such as nausea last? Applies to Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition, with Wegovy tablets (pill)
Note: These median durations are from OASIS 4 (Wegovy 25 mg tablets vs placebo) on the safety profile page of the Wegovy HCP site; the Prescribing Information does not report them.
How common is nausea on the Wegovy injection? Applies to Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition
“In clinical trials in adults for weight reduction, 73% of WEGOVY®
injection-treated patients and 47% of patients receiving placebo
reported gastrointestinal adverse reactions, including severe
reactions that were reported more frequently among patients
receiving WEGOVY® injection (4.1%) than placebo (0.9%). The most
frequently reported reactions were nausea (44% vs. 16%), vomiting
(25% vs. 6%), and diarrhea (30% vs. 16%). Other reactions that
occurred at a higher incidence among WEGOVY® injection-treated
adult patients included dyspepsia, abdominal pain, abdominal
distension, eructation, flatulence, gastroesophageal reflux disease,
gastritis, hemorrhoids, and hiccups. These reactions were most
frequently reported during dosage escalation.” (opens the source at this quote in a new tab) Copy Flag
How long does nausea last on Wegovy HD (STEP UP)? Applies to Weight reduction in adults with obesity with the 7.2 mg once-weekly dose (Wegovy HD)
Note: These passages are from the STEP UP section of the safety profile page of the Wegovy HCP site; STEP UP compared Wegovy HD 7.2 mg, Wegovy 2.4 mg, and placebo. The page text does not state which STEP UP arm the 6-day median nausea duration describes; the accompanying chart is an image.
How can Wegovy nausea and stomach side effects be reduced? Applies to Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition
Note: The eating suggestions are from the dosing page of the Wegovy HCP site, which cites published references; they do not appear in the Prescribing Information.
How many people stop taking Wegovy because of side effects? Applies to Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition
Note: The last passage is from the trial of WEGOVY 25 mg tablets (Study 7).
Does Wegovy cause hair loss? Applies to Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition
“Hair loss adverse reactions in WEGOVY® injection-treated patients
were associated with weight reduction. In a pool of studies 2, 3, and
4, hair loss was reported in 3.3% of patients treated with WEGOVY®
2.4 mg (4% female, 0.9% male) and in 1% of patients treated with
placebo (2% female, 0 male). In a pediatric trial, hair loss was
reported in 4% of patients treated with 2.4 mg of WEGOVY® and
no placebo-treated patients.
In clinical trials with WEGOVY® 7.2 mg injection, hair loss was
reported in 5.8% of patients treated with WEGOVY® 7.2 mg (8.4%
female, 0.2% male), 3.3% of patients treated with WEGOVY® 2.4
mg (5.4% female, 0 male), and 1.0% of patients on placebo (1.5%
female, 0 male). In the WEGOVY® 7.2 mg group, 1 event led to
permanent treatment discontinuation, 1 event led to temporary
interruption, and 5 events led to dose reduction, versus none of
these actions in the WEGOVY® 2.4 mg or placebo groups.” (opens the source at this quote in a new tab) Copy Flag
Does Wegovy HD 7.2 mg cause skin pain, tingling, or burning (dysesthesia)? Applies to Weight reduction in adults with obesity with the 7.2 mg once-weekly dose (Wegovy HD)
“Dysesthesia, and related events of altered skin sensations including
paresthesia, pain of skin, sensitive skin, and burning skin sensation,
occurred in clinical trials with WEGOVY® injection and tablet. The
incidence of dysesthesia with WEGOVY® increased with increasing
dosage and drug levels in the blood.
In clinical trials evaluating patients with and without type 2 diabetes
mellitus, WEGOVY® 7.2 mg injection dysesthesia was reported
at a higher rate in the WEGOVY® 7.2 mg injection group (22%),
compared to WEGOVY® 2.4 mg injection (6%) and placebo (0.3%).
Among 288 patients who experienced dysesthesia with WEGOVY®
7.2 mg injection, 2% permanently discontinued treatment, 8%
had temporary interruption, and 23% had dose reduction; most
subjects with these actions taken to WEGOVY® 7.2 mg injection
(permanent discontinuation, temporary interruption, or dose
reduction) recovered from the event. When an action was taken
with WEGOVY® , events resolved faster than the events where no
action was taken with WEGOVY® . Among patients who experienced
dysesthesia with WEGOVY® 7.2 mg injection, 18% did not report
recovering during the trial duration; in most of the patients who
did not recover, the WEGOVY® dosage was unchanged and not
discontinued. Of the patients who recovered after action taken
with WEGOVY® , 38 patients were re-escalated to 7.2 mg. Of
these 38 patients, 17 (45%) subsequently reported recurrence
of dysesthesia.
In a clinical trial with WEGOVY® 25 mg tablets, 5% of WEGOVY® -
treated patients and no placebo-treated patients reported
dysesthesia adverse reactions.” (opens the source at this quote in a new tab) Copy Flag
Can Wegovy cause low blood pressure or fainting? Applies to Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition